Ipsen/Braintree register bowel cleansing product in Europe
This article was originally published in Scrip
Executive Summary
Ipsen and its partner Braintree Laboratories have completed European decentralized registration of the companies' bowel cleansing product Eziclen/Izinova (BLI-800), and following national decisions on the product, they anticipate launch by the end of 2013.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.